About Us

We are a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia with our lead product Feraccru® / Accrufer™ (Ferric Maltol)

Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives

At a glance

Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia.

Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.

Our lead product Feraccru®/Accrufer™ is a novel, stable, non-salt based oral therapy and is approved in the European Union, the United States and Switzerland for the treatment of iron deficiency with or without anaemia in adults. In Europe it is marketed as Feraccru® with commercialisation led by Norgine BV. We are currently selecting a partner for the US where the product will be marketed as Accrufer™.

We also have an active product pipeline and work with partners globally.

CEO and Co Founder

Carl Sterritt

Over the last few years Shield has transformed itself from a development-focused private company into a publicly listed commercial-stage international pharmaceutical company focused on providing patients and prescribers with novel products that provide solutions to unmet medical needs so we can deliver value to our shareholders.

We were delighted that the FDA approved our lead product Accrufer™ in July 2019 opening up the largest and most attractive reimbursed pharmaceutical market. Accrufer™/ Feraccru® is now approved by the FDA, EMA and Swiss Medic for the treatment of iron deficiency with or without anaemia in adults. In Europe our partner Norgine BV continues to make good progress in leading the commercialisation of Feraccru®.

What sets us apart

  • Lead product Feraccru® / Accrufer™

    Our lead product is approved for the treatment of iron deficiency with or without anaemia in adults in the European Union, the United States and Switzerland and has exclusive IP rights until the mid-2030s .  In Europe it is marketed as Feraccru® with commercialisation led by Norgine BV and in the USA the product – which benefits from NCE exclusivity until 2024 – will be marketed as Accrufer™.

  • Large market opportunities with unmet needs

    The US is the world’s largest and most attractively reimbursed pharmaceutical market. There are between 8 million and 9 million patients in the USA who suffer from iron deficiency anaemia and potentially two to three times this number require treatment for iron deficiency. Our lead product is approved by the FDA and will be marketed in the US as Accrufer™.

    In Europe our lead product is marketed as Feraccru® and is available to treat the estimated 40 million people with iron deficiency, representing another significant commercial opportunity.

  • Experienced management team with extensive expertise

    The skilled senior management team and board of directors provide strong leadership for the Company’s future growth.

  • Strong intellectual property protection

    The Group’s assets are supported by a suite of robust intellectual property rights including key patents in major markets. Feraccru® / Accrufer™, for the treatment of Iron Deficiency with or without anaemia in adults benefits from data exclusivity protection in Europe and the USA and has exclusive IP rights until the mid-2030’s.

  • Investment Case - STX Fact Sheet

    Read more about the Group’s strong investment case here